Compare Twist Bioscience Corp (TWST) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Unity Software Inc — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Unity Software Inc trades at $42 (market cap $18.81B). The key difference: Unity Software Inc is far larger — about 2.2× Twist Bioscience Corp's market cap. Which is the better fit depends on your goals.
| TWST | U | |
|---|---|---|
Market Cap | $8.42B | $18.81B |
Sector | Health | Technology |
52-Week High | $153.10 | $49.47 |
52-Week Low | $24.16 | $17.13 |
Enterprise Value | $8.35B | $18.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Unity Software (U) trades at $42.75, up 2.62% with bullish technical signals and strong analyst support. The company shows improving fundamentals with revenue stabilizing around $1.8B and narrowing losses, though still reporting negative net income. Recent Q2 2026 earnings beat expectations, while institutional activity shows mixed positioning with some major funds increasing stakes. Technical indicators suggest bullish momentum with support at $41 and resistance at $44.
The outlook remains cautiously optimistic with 81% analyst buy ratings and $47.45 price target, representing 11% upside. Key opportunities include Vector platform growth and margin expansion, while risks center on sustained profitability challenges and competitive pressures in the gaming/ad tech space. Execution on strategic initiatives will be critical for stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
